Following the transaction, financial terms of which were not discosed, Pharmapace will become a wholly-owned subsidiary of WuXi AppTec’s clinical contract research organization (CRO) arm, WuXi Clinical.
Pharmapace, a US-based clinical research services company, provides biometrics services across all phases of clinical trials, including clinical and statistical programming, data management, biostatistics, clinical data integration, and medical writing.
Based in San Diego, CA, the addition of Pharmapace enables WuXi Clinical to provide global customers with around-the-clock service.
“This acquisition further enhances WuXi Clinical’s drug development expertise and biometrics capabilities and lays the foundation for the creation of an integrated global biometrics service platform to efficiently and cost-effectively provide customers seamless biometrics services globally,” said Edward Hu, co-CEO of WuXi Apptec in a statement.
In addition to providing full clinical development services, WuXi clinical is a functional service provider (FSP).
Larry Shen, president and CEO of Pharmapace, added, “This combination now allows us to leverage WuXi Apptec’s vast resources to offer customers a truly global solution from preclinical development to clinical development and regulatory submission.”
WuXi AppTec has not responded to a request for comment.
Chinese regulatory reform
After the passing of regulatory reforms, China can now accept clinical trial data from outside countries, creating opportunities for regional and global collaboration.
Following this change, among other recent reforms, WuXi AppTec acquired US-based ResearchPoint Global to expand its clinical research capabilities.
With the acquisition of Pharmapace, WuXi Clinical will have more than 850 employees in China and the US.
